Prevention of CMV disease in pediatric kidney transplant recipients: Evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients

Pediatric Transplantation

Volumn 12, Issue 4, 2008, Pages 420-425

  Renoult, Edith ^a   Clermont, Marie José ^a   Phan, Véronique ^a   Buteau, Chantal ^a   Alfieri, Carolina ^a   Tapiero, Bruce ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Cytomegalovirus; Pediatric renal transplant patients; pp67 nucleic acid sequence based amplification assay; Pre emptive therapy

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN PP67; GANCICLOVIR; IMMUNOGLOBULIN; MESSENGER RNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS ANTIGEN;

ADOLESCENT; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; EVALUATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MYCOSIS; NUCLEIC ACID SEQUENCE BASED AMPLIFICATION; QUALITATIVE ANALYSIS; RECIPIENT; RELAPSE; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; VIREMIA; VIRUS DETECTION;

ADOLESCENT; CHILD; CYTOKINES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; PHOSPHOPROTEINS; RETROSPECTIVE STUDIES; SELF-SUSTAINED SEQUENCE REPLICATION; TREATMENT OUTCOME; VIRAL MATRIX PROTEINS;

EID: 43249121337     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00799.x     Document Type: Article

References (33)

1. Sagedal S, Nordal KP, Hartmann A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000 : 70 : 1166 1174.
2. Gagnadoux MF, Niaudet P, Broyer M. Non-immunological risk factors in paediatric renal transplantation. Pediatr Nephrol 1993 : 7 : 89 95.
3. Li L, Chaudhuri A, Weintraub LA, et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007 : 11 : 187 195.
4. Robinson LG, Hilinski J, Graham F, et al. Predictors of cytomegalovirus disease among pediatric transplant recipients within one year of renal transplantation. Pediatr Transplant 2002 : 6 : 111 118.
5. Small NL, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: A meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006 : 43 : 869 880.
6. Tan BH. CMV prophylaxis - to do or not to do, that is the question. Nephrol Dial Transplant 2006 : 21 : 1757 1761.
7. Chou SW. Cytomegalovirus drug resistance and clinical implications. Transplant Infect Dis 2001 : 3 : 20 24.
8. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: A call to heed the mounting evidence. Clin Infect Dis 2005 : 40 : 704 708.
9. Blok MJ, Lautenschlager I, Goossens VJ, et al. Diagnostic implications of human cytomegalovirus immediate early-1 and pp67 mRNA detection in whole-blood samples from liver transplant patients using nucleic acid sequence-based amplification. J Clin Microbiol 2000 : 38 : 4485 4491.
10. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990 : 28 : 495 503.
11. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002 : 34 : 1094 1097.
12. Gerna G, Baldanti F, Lilleri D, et al. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: A prospective, randomized, controlled, open-label trial. Transplantation 2003 : 75 : 1012 1019.
13. Goossens VJ, Vink C, Mullers W, Middeldorp JM, Bruggeman CA. Different profiles of cytomegalovirus RNA transcripts and anti-cytomegalovirus IgM antibodies in renal transplant recipients. J Clin Virol 2001 : 23 : 87 95.
14. Seehofer D, Meisel H, Rayes N, et al. Prospective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation. Am J Transplant 2004 : 4 : 1331 1337.
15. Snydman DR. Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transplant Infect Dis 2001 : 3 : 6 13.
16. Bok GH, Sullivan EK, Miller D, et al. Cytomegalovirus infections following renal transplantation - effects of antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997 : 11 : 665 671.
17. Snydman DR, Werner BG, Heinze-Lacey B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987 : 317 : 1049 1054.
18. Fontana I, Verrina E, Timitilli A, et al. Cytomegalovirus infection in pediatric kidney transplantation. Transplant Proc 1994 : 26 : 18 19.
19. Staskewitz A, Kirste G, Tönshoff B, et al. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment. Transplantation 2001 : 71 : 638 644.
20. Melgosa Hijosa M, Garcia Meseguer C, Pena Garcia P, et al. Preemptive treatment with oral ganciclovir for pediatric renal transplantation. Clin Nephrology 2004 : 61 : 246 252.
21. Ter Meulen CG, Wetzels JFM, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000 : 15 : 711 714.
22. Muheim V, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ transplant patients. Transplantation 2002 : 74 : 226 236.
23. Ginevri E, Losurdo G, Fontana I, et al. Acyclovir plus CMV immunoglobulin prophylaxis and early therapy with ganciclovir are effective and safe in CMV high-risk renal transplant pediatric recipients. Transpl Int 1998 : 11 (Suppl. 1 S130 S134.
24. Varga M, Remport A, Hidvégi M, et al. Comparing cytomegalovirus prophylaxis in renal transplantation: Single center experience. Transpl Infect Dis 2005 : 7 : 63 67.
25. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004 : 4 : 611 620.
26. Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis 2003 : 187 : 1801 1808.
27. Rayes N, Seehofer D, Schmidt CA, et al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation. Transplantation 2001 : 72 : 881 885.
28. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997 : 176 : 1484 1490.
29. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000 : 355 : 2032 2036.
30. Addo MM, Rosenberg ES. Cellular immune responses in transplantation- associated chronic viral infections. Transplant Infect Dis 2002 : 4 : 31 40.
31. Clark BS, Chang IF, Karpen SJ, et al. Valganciclovir for the prophylaxis of cytomegalovirus disease in pediatric liver transplant recipients. Transplantation 2004 : 77 : 1480.
32. Vethamuthu J, Feber J, Chretien A, Lampe D, Filler G. Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 2007 : 11 : 301 305.
33. Bouw R, Vaudry W, Walker R, et al. Ganciclovir Pharmacokinetics in Pediatric Solid Organ Transplant Recipients After Administration of Valganciclovir Oral Solution. Boston, MA : World Transplant Congress, 2006 : p. 215 (abstract no. 442).